Neoadjuvant Chemo for Ovarian Ca Highlighted in New Guidelines (ASCO/SGO)

medscape

 Neoadjuvant chemotherapy is the preferred treatment option for women with advanced ovarian and related cancers if it is unlikely that primary cytoreductive surgery (PCS) can reduce disease to less than 1 cm. It is also an alternative to surgery for women with potentially resectable disease who prefer the neoadjuvant approach, as chemotherapy is not inferior to surgery in terms of progression-free or overall survival, new guidelines indicate.
The new guidelines were issued jointly by the American Society of Clinical Oncology and the Society of Gynecologic Oncology and were published online August 8 in the Journal of Clinical Oncology and Gynecologic Oncology.
"For a long time, physicians assumed that doing immediate surgery when a woman was diagnosed with ovarian cancer was the best possible treatment," lead author Alexi Wright, MD, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, told Medscape Medical News.....